Literature DB >> 26279153

Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.

K Curran1, D H Thamm1,2,3.   

Abstract

Standard of care treatment of dogs with multicentric lymphoma includes combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); however, owners may be hesitant to commit the resources necessary to complete a lengthy, multi-drug protocol. One hundred thirty-four client-owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol. The overall response rate was 98% with 104 dogs experiencing a complete response (CR). The median progression-free survival (PFS) time for all dogs was 176 days, and the median disease-specific overall survival time was 311 days. Prognostic factors identified on multivariate analysis as significant for PFS included substage, immunophenotype, hospitalization for adverse events, need for dose reduction, presence of neutrophilia at diagnosis, presence of anemia and experiencing a CR as best response to therapy. In conclusion, this protocol may be a viable alternative to CHOP protocols using a larger number of treatments.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  chemotherapy; dog; lymphoma; lymphosarcoma; small animal

Mesh:

Substances:

Year:  2015        PMID: 26279153     DOI: 10.1111/vco.12163

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  12 in total

1.  Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma.

Authors:  E L Moore; W Vernau; R B Rebhun; K A Skorupski; J H Burton
Journal:  Vet Comp Oncol       Date:  2017-06-28       Impact factor: 2.613

Review 2.  Barking up the right tree: advancing our understanding and treatment of lymphoma with a spontaneous canine model.

Authors:  Dania Villarnovo; Angela L McCleary-Wheeler; Kristy L Richards
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

3.  Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.

Authors:  Q Fournier; J-C Serra; I Handel; J Lawrence
Journal:  J Vet Intern Med       Date:  2017-12-04       Impact factor: 3.333

4.  Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.

Authors:  D H Thamm; D M Vail; G S Post; T M Fan; B S Phillips; S Axiak-Bechtel; R S Elmslie; M K Klein; D A Ruslander
Journal:  J Vet Intern Med       Date:  2017-04-03       Impact factor: 3.333

5.  Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma.

Authors:  Kelly R Hume; Skylar R Sylvester; Lucia Borlle; Cheryl E Balkman; Angela L McCleary-Wheeler; Mary Pulvino; Carla Casulo; Jiyong Zhao
Journal:  Front Vet Sci       Date:  2018-02-26

6.  Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma.

Authors:  Joseph A Impellizeri; Alessandra Gavazza; Eliana Greissworth; Anna Crispo; Maurizio Montella; Gennaro Ciliberto; George Lubas; Luigi Aurisicchio
Journal:  J Transl Med       Date:  2018-12-11       Impact factor: 5.531

7.  Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

Authors:  Pierre Boyé; Franck Floch; François Serres; Kévyn Geeraert; Pierre Clerson; Xavier Siomboing; Mattias Bergqvist; Gabriel Sack; Dominique Tierny
Journal:  J Vet Intern Med       Date:  2019-05-25       Impact factor: 3.333

8.  Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy.

Authors:  Paweł Klimiuk; Wojciech Łopuszyński; Kamila Bulak; Adam Brzana
Journal:  Animals (Basel)       Date:  2021-04-20       Impact factor: 2.752

9.  Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma.

Authors:  Sami Al-Nadaf; Robert B Rebhun; Kaitlin M Curran; Rachel O Venable; Katherine A Skorupski; Jennifer L Willcox; Jenna H Burton
Journal:  BMC Vet Res       Date:  2018-11-20       Impact factor: 2.741

10.  Predicting Dynamic Clinical Outcomes of the Chemotherapy for Canine Lymphoma Patients Using a Machine Learning Model.

Authors:  Jamin Koo; Kyucheol Choi; Peter Lee; Amanda Polley; Raghavendra Sumanth Pudupakam; Josephine Tsang; Elmer Fernandez; Enyang James Han; Stanley Park; Deanna Swartzfager; Nicholas Seah Xi Qi; Melody Jung; Mary Ocnean; Hyun Uk Kim; Sungwon Lim
Journal:  Vet Sci       Date:  2021-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.